Ketamine Microdosing vs Full-Dose Treatment: What's the Difference?

The concept of microdosing has entered mainstream consciousness in recent years, driven largely by interest in psilocybin and LSD for productivity and mood enhancement. This cultural moment has naturally led patients to ask about microdosing ketamine -- taking very small, sub-perceptual doses on a regular schedule rather than full therapeutic doses in structured sessions. It is a reasonable question, but the answer requires understanding what microdosing actually means, what the clinical evidence shows, and why the dosing strategy matters as much as the molecule itself.

Defining the Terms

The language around ketamine dosing can be imprecise, so let me establish clear definitions.

Microdosing refers to taking a fraction of a standard therapeutic dose -- typically one-tenth to one-twentieth -- on a regular schedule (daily or every few days). At these doses, the person experiences no noticeable psychoactive effects. There is no dissociation, no perceptual changes, and no altered state of consciousness. The idea is that sub-perceptual doses may produce cumulative neurochemical benefits without the acute experience.

Full therapeutic dose refers to the dose range used in clinical ketamine therapy for depression. At these doses, patients experience noticeable effects including dissociation, altered perception, and changes in body awareness. The session is a distinct experience that lasts approximately 45 to 90 minutes, followed by a recovery period. This is the dosing approach used at Tovani Health and in the vast majority of published clinical research.

Sub-therapeutic but perceptible doses occupy a middle ground -- enough to notice subtle effects but well below the threshold for a full dissociative experience. Some providers use this range, but it lacks the robust clinical evidence base of either extreme.

The Clinical Evidence for Full-Dose Ketamine

The research supporting ketamine for treatment-resistant depression is built almost entirely on full therapeutic doses. The landmark studies that established ketamine as a rapid-acting antidepressant used intravenous doses of 0.5 mg/kg -- a dose that reliably produces dissociative effects. Subsequent research using sublingual, intramuscular, and intranasal routes has used equivalent dosing strategies that similarly produce noticeable psychoactive effects.

This body of evidence is substantial. Multiple randomized controlled trials, meta-analyses, and real-world clinical studies consistently show that full-dose ketamine produces:

• Rapid antidepressant effects within hours to days
• Response rates of 60 to 70 percent in treatment-resistant patients
• Measurable increases in synaptic connectivity in prefrontal brain regions
• Significant elevations in BDNF (brain-derived neurotrophic factor)
• Detectable changes in default mode network activity

The mechanism by which ketamine works -- NMDA receptor blockade triggering a glutamate cascade that promotes synaptogenesis -- has been demonstrated at full therapeutic doses. Whether the same cascade occurs at microdoses is an open question with limited evidence.

The Clinical Evidence for Ketamine Microdosing

In contrast to the robust evidence base for full-dose treatment, the evidence for ketamine microdosing for depression is sparse. There are no large, randomized, controlled trials demonstrating that sub-perceptual ketamine doses produce meaningful antidepressant effects.

What does exist:

• Preclinical (animal) studies showing that very low doses of ketamine can produce some behavioral changes in animal models of depression. However, translating rodent dose-response data to human clinical practice is unreliable.
• Anecdotal reports from patients and some providers claiming benefit from low-dose ketamine protocols. Anecdotal evidence is valuable for generating hypotheses but cannot establish efficacy due to the powerful influence of placebo effects, expectation, and natural symptom fluctuation.
• Small, uncontrolled case series with mixed results and significant methodological limitations.

This does not mean microdosing definitely does not work. It means we do not have sufficient evidence to know whether it works, how well it works, or for whom it might be appropriate. In medicine, the distinction between "unproven" and "disproven" matters.

Why the Dissociative Experience May Matter

One of the most debated questions in ketamine research is whether the dissociative experience itself contributes to therapeutic outcomes or whether it is merely a side effect of the dose needed to trigger the underlying neurochemistry.

Emerging evidence suggests the experience may be therapeutically relevant:

Psychological processing. During a full-dose session, patients often gain new perspectives on their depression, relationships, and life circumstances. This perspective shift -- sometimes described as seeing your problems from outside yourself -- can catalyze meaningful psychological change. Microdoses, by definition, do not produce this experience.

Pattern interruption. The dissociative state temporarily disrupts the rigid, repetitive thought patterns that characterize depression. This interruption may help the brain "reset" and allow new patterns to form. There is no pattern interruption at sub-perceptual doses.

Default mode network modulation. Full-dose ketamine significantly alters activity in the default mode network -- the brain system associated with self-referential thinking and rumination. This disruption correlates with therapeutic benefit. Whether microdoses affect the DMN meaningfully is unknown.

Dose-response relationship. Studies that have examined different doses find a clear dose-response relationship, with higher doses (within the therapeutic range) generally producing stronger antidepressant effects. This suggests that the neurobiological changes ketamine triggers are dose-dependent and may not occur at micro-level doses.

The BDNF and Neuroplasticity Question

The core therapeutic mechanism of ketamine involves triggering a surge of BDNF and rapid synaptogenesis -- the growth of new synaptic connections. This process has been clearly demonstrated at full therapeutic doses through both animal studies and human neuroimaging research.

The critical question for microdosing is whether sub-perceptual doses produce enough NMDA receptor blockade to initiate this cascade. The NMDA blockade that triggers the glutamate surge requires a certain threshold of receptor occupancy. At a tenth of a therapeutic dose, it is unclear whether this threshold is met.

Think of it this way: a match needs a minimum amount of friction to ignite. You can move a match slowly across a striking surface all day without generating enough heat to produce a flame. The same principle may apply to ketamine's neuroplasticity cascade -- there may be a minimum effective dose below which the mechanism simply does not engage.

Why Tovani Health Uses Full Therapeutic Doses

Our treatment protocol at Tovani Health is built on full therapeutic doses for several straightforward reasons:

Evidence-based practice. We prescribe based on what has been demonstrated to work in clinical research. The evidence for full-dose ketamine therapy is robust. The evidence for microdosing is not yet sufficient to support clinical use.

Accountability to patients. When someone invests time, money, and hope in treatment, they deserve a protocol with the strongest probability of success. Offering a less-studied approach when a well-studied one is available would not serve our patients' interests.

Measurable outcomes. Full-dose treatment produces effects that can be objectively tracked -- symptom scores, functional improvement, and patient-reported outcomes. This allows us to determine quickly whether treatment is working and make adjustments if it is not.

Safety infrastructure. Our safety protocols -- support person requirement, blood pressure monitoring, activity restrictions -- are specifically designed for full-dose sessions. The controlled, structured nature of our approach ensures that the therapeutic experience occurs within a framework designed to maximize both safety and benefit.

Addressing Common Patient Concerns About Full Doses

Patients who ask about microdosing often have underlying concerns that full-dose treatment raises. Let me address these directly.

"I am afraid of the dissociative experience." This is completely understandable. The idea of an altered state of consciousness is unfamiliar and can feel threatening. In practice, most patients find the experience far less frightening than anticipated. The dissociation is gentle, time-limited, and occurs in the safety of your own home with a support person present. Many patients come to view the sessions as a valued part of their treatment.

"I do not want to be impaired." Full-dose ketamine does involve temporary impairment and 24-hour activity restrictions. But this occurs only on treatment days -- not daily. Between sessions, there is no ongoing impairment. Microdosing's appeal of no noticeable effects comes with the significant trade-off of no proven efficacy.

"I want something I can take daily without disruption." If a daily oral medication is the right fit for your lifestyle, there are many evidence-based daily antidepressants to consider. Ketamine therapy is a different model -- periodic, intensive sessions rather than daily maintenance. Its strength lies in that periodic intensive approach.

"I have read online that microdosing works." Online testimonials, influencer content, and wellness marketing can be persuasive but should not substitute for clinical evidence. I encourage patients to ask their clinicians about the quality of evidence behind any treatment claim.

The Future May Change the Equation

Science evolves, and it is entirely possible that future research will demonstrate effective microdosing protocols for ketamine. If rigorous clinical trials show that sub-perceptual doses produce meaningful, reliable antidepressant effects, the practice of ketamine therapy will and should adapt accordingly.

But we are not there yet. Current practice should be guided by current evidence, and current evidence strongly supports full therapeutic dosing.

Finding the Right Approach for You

If you are considering ketamine therapy and have questions about dosing, the treatment experience, or any other aspect of care, our evaluation process is designed to address them. We believe informed patients make better treatment decisions, and we are committed to providing honest, evidence-based information.

Check your eligibility for ketamine therapy with Tovani Health. Our clinicians will explain exactly what to expect from treatment, answer your questions thoroughly, and help you decide whether this approach is right for your situation.